Disc Medicine(IRON) - 2023 Q4 - Annual Results

Exhibit 99.1 Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Recent Business Highlights and Upcoming Milestones: Bitopertin: GlyT1 Inhibitor (Heme Synthesis Modulator) • Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024 • On track to deliver multiple read-outs in 2024, including updated results from phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF) ...